Craig Eisentrout, MD
Pulmonary Disease · Cincinnati, OHNPI 1801980164
Payments from drug & device makers
Across 296 payments — averaging $56.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- GSK$699
- AstraZeneca$639
- Boehringer Ingelheim$514
- Sanofi$333
- Grifols USA, LLC$127
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$4,00024%
- Travel & lodging$4,37426%
- Food & beverage$5,18431%
- Education$3,06918%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 51 | $12,906 |
| GSK | 62 | $699 |
| AstraZeneca | 42 | $639 |
| Boehringer Ingelheim | 37 | $514 |
| Sanofi | 17 | $333 |
| Grifols USA, LLC | 7 | $127 |
| Tempus AI, Inc | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 8 | $118 |
| Galvanize Therapeutics, Inc | 1 | $116 |
| Mylan Specialty L.p. | 7 | $112 |
| Sunovion Pharmaceuticals Inc. | 7 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $81 |
| Insmed, Inc. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Electromed, Inc. | 5 | $56 |
| Covis Pharma GmbH | 3 | $53 |
| Philips North America LLC | 3 | $47 |
| Merck | 3 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Astellas Pharma US Inc | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| United Therapeutics Corporation | 2 | $33 |
| Circassia Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Pfizer | 2 | $30 |
| Novartis | 2 | $29 |
| CSL Behring | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 2 | $26 |
| Gilead | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| Bio Products Laboratory USA, Inc. | 1 | $11 |
| Acacia Pharma Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,399
- DA VINCI SP$1,000
- ALIYA SYSTEM$116
How this compares
$16,627 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $195,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $98,453 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $51,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $47,135 |
| Spiriva RespimatTiotropium Bromide | 29 | $24,873 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $24,223 |
| DuleraMometasone/Formoterol | 44 | $23,965 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $19,942 |
| Arnuity ElliptaFluticasone Furoate | 40 | $19,693 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $13,977 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 60 | $11,683 |
| Pulmicort FlexhalerBudesonide | 23 | $9,029 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,054 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,020 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $6,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $514 | $244,91378 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $699 | $191,214279 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $639 | $76,107113 claims |
| MerckDulera | $45 | $23,96544 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $60 | $6,12014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Bruce CorserCincinnati$8.2M
- Jean ElwingCincinnati$2.4M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Mohammad SheattCincinnati$405K
- Robert BurkesCincinnati$299K
- Arun JoseCincinnati$287K
- Bruce TrapnellCincinnati$153K
- Rachel FootCincinnati$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.